In brief
Prescription drugs are unaffordable mainly because of administrative layers and opaque pricing rather than production cost. Ezekiel Emanuel and Miriam Paramore argue for splitting the market in two: make generics free at the pharmacy counter, with a few safe old drugs sold over the counter, and use government price regulation for expensive brand-name drugs, where patients cannot realistically shop around.
The tension runs between consumer power and its limits. Paramore shows that direct-to-consumer sales, as with Eliquis and GLP-1 drugs, quickly cut prices when patients can see and pay them. Emanuel counters that no patient can shop for a $10,000-a-month cancer drug, so regulation is needed. Both agree the web of rebates and middlemen adds little value and should be simplified or removed.
Questions
Why are prescription drugs so expensive in the US if many cost pennies to make?
Emanuel says administrative add-ons around generic drugs cost far more than producing and selling them. He and Paramore also say many middlemen take a share of the money while adding little or no value.
What is the difference between a drug's list price and its net price?
Paramore says the list price is a 'made up' number that patients may pay when they haven't met their deductible. Insurers, PBMs and employers pay the lower net price, which for Dupixent she says is about $1,000 against a $2,500 to $4,000 list price.
What do Emanuel and Paramore propose for cheap generic drugs?
They propose removing copays and deductibles for tier-one generics so patients actually take them. They also want a small set of old, proven-safe drugs, perhaps 30 to 40, sold over the counter.
Should we get rid of pharmacy benefit managers (PBMs)?
Emanuel says probably yes, if drug pricing is changed so all drugs in a class cost the same, because a PBM's main job is negotiating a preferred-drug list. He says a distributor function would still be needed.
Can shopping around bring down the cost of cancer drugs?
Becker and Emanuel say no. Patients can't realistically price-shop for cancer or cardiovascular treatment, so consumer pressure works for generics but expensive brand drugs need regulation.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Ezekiel Emanuel worked at the White House Office of Management and Budget and National Economic Council between 2009 and 2011 on the Affordable Care Act.
“Between 2009 and 2011, I was in the White House at the Office of Management and Budget and the National Economic Council, working on the Affordable Care Act”
0:02:27 · Ezekiel Emanuel · Career · 2009-2011
Ezekiel Emanuel is a professor and vice provost of global initiatives at the University of Pennsylvania.
“And then I came to the University of Pennsylvania, where I am a professor and a vice provost of global initiatives”
0:03:05 · Ezekiel Emanuel · Career
Miriam Paramore is the founder and CEO of RxUtility, a company focused on helping people save money on medicine.
“I'm the founder and CEO of RxUtility, and I'm not famous.”
0:00:48 · Miriam Paramore · RxUtility
Miriam Paramore's sister was diagnosed with breast cancer about two years before the recording and had a double mastectomy.
“My sister was diagnosed with breast cancer two years ago, had a double mastectomy.”
0:08:10 · Miriam Paramore · Breast cancer
According to Paramore, on the morning of her sister's mastectomy, check-in staff told the sister that Cigna had denied coverage for her anesthesiologist.
“And they said, Cigna has denied your anesthesiologist.”
0:08:47 · Miriam Paramore · Insurance denials
Paramore says there are now more price points for the same drug than ever before, including a direct-to-patient manufacturer channel that did not exist until last year.
“we have more price points for the same drug than we've ever had before.”
0:13:27 · Miriam Paramore · Drug pricing
Paramore says payers, pharmacy benefit managers and employers pay based on net price, while patients in a deductible phase may pay the higher list price.
“the payers, the PBMs and the employers, they all pay off of net.”
0:13:56 · Miriam Paramore · List vs net price
Paramore credits GoodRx with shifting the industry by arguing people should know what drugs cost, and says its business began about 12 years before the recording.
“GoodRx made a great shift in our industry when they said, we think people should know what drugs cost”
0:15:03 · Miriam Paramore · Price transparency
Paramore says the PBM reform policy would include TrumpRx prices in real-time pharmacy benefit checks, though she notes TrumpRx lacks some drugs and is not always cheapest.
“And the other thing is they're saying we should include the Trump Rx prices in the real-time pharmacy benefit check return.”
0:16:07 · Miriam Paramore · PBM reform
Scott Becker says about 31 million people are on GLP-1 drugs, with many now obtaining them through direct-to-consumer channels rather than insurers.
“31 million people are on GLP-1s. A huge percentage of those are getting them now, not through payers”
0:17:34 · Scott Becker · GLP-1 drugs
Becker says Cigna or Aetna recently stopped covering GLP-1 drugs for employees, since cheaper direct options exist; he was unsure which insurer.
“Cigna recently, I think it was Cigna or Aetna recently said they're no longer covering for their employees”
0:18:25 · Scott Becker · GLP-1 coverage
Paramore says Eliquis's list price for patients paying out of pocket in the deductible phase was $600 before direct-to-consumer sales.
“list price that patients are paying out of their own pocket when they're in their deductible phase for Eliquis was $600.”
0:19:39 · Miriam Paramore · Eliquis pricing
Paramore says Eliquis's direct-to-consumer price is now $349, and about $249 from a Canadian pharmacy.
“$349. And do you know if you get it from a Canadian pharmacy, it's $249.”
0:20:10 · Miriam Paramore · Eliquis pricing
Becker cites Civica, which he links to Intermountain, as a nonprofit effort to provide generic drug alternatives.
“you've seen Civica coming out of Intermountain try and provide an ability or a bunch of nonprofits, but trying to provide a generics alternative”
0:12:52 · Scott Becker · Generic drugs
Emanuel says roughly 90% of prescriptions in the US are for generic drugs.
“whatever, 90 % of prescriptions are generic drugs.”
0:22:41 · Ezekiel Emanuel · Generics
Emanuel says a handful of 30 to 40 drugs, in use for 60 to 70 years, are safe enough to be sold over the counter, and calls them safer than Tylenol and aspirin.
“We know they're safe. We've been using them for 60, 70 years. They're safer than Tylenol and Aspen.”
0:23:50 · Ezekiel Emanuel · OTC drugs
Emanuel says the US is one of the few countries that grants drug patents and then lets companies set the price freely.
“we're one of the only countries that gives drug companies patents and then says, set the price.”
0:24:22 · Ezekiel Emanuel · Drug regulation
Emanuel favors an Australia-inspired system where a new drug class gets one price, and later 'me too' drugs get lower prices.
“My own favorite idea, it really comes out of Australia, I mean, which is you get a price for a new class of drugs.”
0:24:59 · Ezekiel Emanuel · Drug pricing
Emanuel says the main job of a pharmacy benefit manager is building a formulary to get better prices for the plan sponsor.
“What's the main focus of a PBM? Putting together a formulary to get the better pricing for the sponsor.”
0:26:53 · Ezekiel Emanuel · PBMs
Paramore says RxUtility aims to be the 'Expedia for drug prices', surfacing all prices so they flow through existing workflows.
“We are hoping to be the Expedia for drug prices, Scott.”
0:29:05 · Miriam Paramore · RxUtility
Scott Becker estimates there are about 27,000 to 28,000 practicing oncologists in the US.
“27 ,000 oncologists in the country practicing or somewhere around there, 27 to 28 ,000.”
0:05:08 · Scott Becker · Oncology workforce